Leerink Partnrs Has Pessimistic View of MNMD Q4 Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Investment analysts at Leerink Partnrs reduced their Q4 2025 earnings estimates for Mind Medicine (MindMed) in a research report issued to clients and investors on Sunday, November 9th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($0.54) for the quarter, down from their prior estimate of ($0.53). The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Mind Medicine (MindMed)’s FY2026 earnings at ($1.95) EPS, FY2027 earnings at ($2.00) EPS and FY2028 earnings at ($2.05) EPS.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its earnings results on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26).

Several other research firms also recently weighed in on MNMD. Oppenheimer started coverage on Mind Medicine (MindMed) in a research report on Monday, August 4th. They set an “outperform” rating and a $25.00 target price on the stock. Canaccord Genuity Group lifted their price objective on Mind Medicine (MindMed) from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Chardan Capital reissued a “buy” rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, August 1st. Royal Bank Of Canada decreased their target price on shares of Mind Medicine (MindMed) from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Friday, November 7th. Finally, Lifesci Capital raised shares of Mind Medicine (MindMed) to a “strong-buy” rating in a report on Tuesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Mind Medicine (MindMed) currently has a consensus rating of “Buy” and an average target price of $26.50.

Mind Medicine (MindMed) Trading Down 4.2%

Shares of MNMD stock opened at $11.63 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.30 and a quick ratio of 3.30. The company has a market cap of $884.90 million, a price-to-earnings ratio of -5.70 and a beta of 2.57. Mind Medicine has a 1 year low of $4.70 and a 1 year high of $14.43. The firm has a fifty day moving average price of $11.51 and a 200-day moving average price of $9.24.

Insider Transactions at Mind Medicine (MindMed)

In other Mind Medicine (MindMed) news, insider Daniel Karlin sold 7,704 shares of the business’s stock in a transaction on Thursday, September 25th. The shares were sold at an average price of $9.77, for a total value of $75,268.08. Following the sale, the insider owned 430,625 shares in the company, valued at $4,207,206.25. The trade was a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert Barrow sold 25,797 shares of the stock in a transaction dated Thursday, September 25th. The shares were sold at an average price of $9.77, for a total transaction of $252,036.69. Following the transaction, the chief executive officer directly owned 804,268 shares of the company’s stock, valued at $7,857,698.36. This trade represents a 3.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 44,779 shares of company stock valued at $437,491. 2.45% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Mind Medicine (MindMed)

A number of hedge funds have recently made changes to their positions in MNMD. Russell Investments Group Ltd. grew its holdings in Mind Medicine (MindMed) by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares in the last quarter. BIT Capital GmbH purchased a new stake in Mind Medicine (MindMed) during the third quarter valued at $26,000. CWM LLC lifted its position in Mind Medicine (MindMed) by 67.4% during the second quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after purchasing an additional 1,796 shares during the last quarter. Fifth Third Bancorp grew its stake in shares of Mind Medicine (MindMed) by 5,593.2% in the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock worth $40,000 after buying an additional 3,300 shares in the last quarter. Finally, Sound Income Strategies LLC bought a new stake in shares of Mind Medicine (MindMed) in the 3rd quarter worth about $46,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.